Aspire Biopharma Holdings, Inc. - Common Stock (ASBP)

TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ), a global leader in disinfection and decontamination, announced a significant expansion commitment from Trauma and Casualty Team (T.A.C.T.), a nationwide franchise network specializing in biohazard cleanup. The initiative underscores TOMI’s mission to create safer, healthier environments by neutralizing dangerous pathogens, mold, and toxins that threaten public health.

Prioritizes High-Value Approved Drugs in Multi-Billion-Dollar Markets to Accelerate Commercialization

BUZZ BOMB™ engages three specialized fitness influencers to grow the brand

Part of New Contract Manufacturing Agreement with SupraNaturals to Secure Additional Production Capacity

Aspire's sublingual aspirin formulation significantly inhibited serum thromboxane B2 (TxB2) within the first two minutes after dosing

NEW YORK CITY, NY / ACCESS Newswire / August 19, 2025 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day August Micro-Cap Conference taking place Wednesday and Thursday, August 20-21, 2025. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links.

According to the NIH, Acute myocardial infarction (AMI) is a major cause of death, affecting nearly 3 million Americans each year and resulting in over a million deaths

ESTERO, FL / ACCESS Newswire / August 14, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug and supplement delivery technology, today announced that Kraig Higginson, Interim Chief Executive Officer of Aspire, will be presenting at the upcoming Sidoti Virtual Investor Conference on August 20 at 1:45 PM Eastern. Investors and other interested individuals may access the virtual presentation here: https://sidoti.zoom.us/webinar/register/WN_5UneWjXKTOuzgbB4wpeByg

BUZZ BOMB™ is bringing its unique delivery technology benefits to the multi-billion-dollar pre-workout to help athletes and fitness enthusiasts maximize their performance potential

First sublingual pre-workout single-serving supplement that delivers 50mg of caffeine rapidly to the body, is now available to order via Aspire's new direct-to-consumer shopping experience

Kraig Higginson, Current Chairman of the Board, Appointed Interim CEO

Sublingual nano technology delivers 50mg of caffeine rapidly to the body, bringing its unique benefits to the pre-workout market

Early positive consumer testimonials from initial Company product sampling

Enrollment Completed on Schedule; Topline Results Expected Mid Q3 2025

Michael Howe - who currently serves as an Independent Board Member - to assume CEO role on June 10, 2025

Sublingual nano technology delivers caffeine rapidly to the blood stream, bringing its unique disruptive benefits to the Pre-workout market

Trial marks key milestone in driving pipeline progress

HUMACAO, PUERTO RICO AND NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today announced that Kraig Higginson, Chief Executive Officer of Aspire, will be presenting at the upcoming Sidoti Virtual Investor Conference on May 21 at 2:30 PM Eastern. Investors and other interested individuals may access the virtual presentation here: https://sidoti.zoom.us/webinar/register/WN_q62DwzilROyKt-kOh_GJDQ

Company achieves another milestone relating to its clinical trial strategy

HUMACAO, PR AND NEW YORK, NY / ACCESS Newswire / April 14, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today announced that Kraig Higginson, CEO of Aspire, will present at the Emerging Growth Conference.

Plans to conduct consumer and safety testing during second quarter 2025

One clinical trial site activated

Subsequent phase involves completion of chemistry, manufacturing, and controls (CMC) testing for data to support FDA submission

HUMACAO, PUERTO RICO AND NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today provided an update on its two patent applications, originally filed as provisional patent applications with the U.S. Patent and Trademark Office ("USPTO") on March 31, 2023 and October 2, 2024, respectively, pertaining to Oral Mucosal Formulations of Aspirin that utilize Aspire's fast acting formulation.

New York, New York--(Newsfile Corp. - March 11, 2025) - Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP) ("Aspire" or the "Company")...